Review Article
Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation
Authors:
Mengqi Liu,
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University; Henan Key Laboratory of Digestive Organ Transplantation, Zhengzhou, Henan, CN
About Mengqi
MD
Wenzhi Guo,
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University; Henan Key Laboratory of Digestive Organ Transplantation, Zhengzhou, Henan, CN
About Wenzhi
PhD
Shuijun Zhang
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Jianshe Road 1, Zhengzhou, Henan; Henan Key Laboratory of Digestive Organ Transplantation, Zhengzhou, Henan, CN
About Shuijun
PhD
Abstract
Cancer immunotherapy, as a new treatment modality, has been shown to be effective, especially in metastatic melanoma and lung cancer. Organ transplantation can be a life-saving procedure for patients with end-stage diseases of lung, heart, kidney and liver. While ironically, as improvements in organ transplantation have extended patients’ lives, new or recurrent postsurgical malignancies have become an increasing threat to their long-term survival, especially in patients after liver transplantation due to hepatocellular carcinoma. The feasibility of immunotherapy treatment for such patients is still to be investigated.
How to Cite:
Liu M, Guo W, Zhang S. Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation. International Journal of Surgery: Oncology. 2017;2(11):e49. DOI: http://doi.org/10.1097/IJ9.0000000000000049
Published on
16 Nov 2017.
Peer Reviewed
Downloads
